Anne Bruinvels joins EPEMED as executive director

Targeted with growing start-up organisation and building its strategic framework

The European Personalised Medicine Diagnostics Association (EPEMED) has appointed Anne Bruinvels, an entrepreneur in personalised healthcare, as executive director and board member.

Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.

‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.

Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.

Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.

You may also like

Packaging

SmartSkin unveils pharma seal assurance solution with real-time insights

The breakthrough solution will give manufacturers real-time visibility into container closure integrity and capping performance, with SmartSkin aiming to debut the technology at the upcoming IPSE 4.0 in Barcelona
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Manufacturing

IDA Ireland releases whitepaper on the future of biopharma manufacturing in Ireland

The report highlights details on Ireland's geopolitical stability, its high regulatory standards and how the country is forging ahead as a leader in the advanced therapy and next-gen biologics sector
Pharma 5.0

Excelsior Sciences raises $95m for AI-powered small molecule discovery and manufacturing

Deerfield Management, Khosla Ventures and Sofinnova Partners co-lead Series A fundraising for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring
Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Contamination Control

Eurofins launches first GMP-compliant PFAS screening solution for the medical device industry

Eurofins Medical Device Services North America has introduced the industry’s first GMP PFAS testing and screening platform, helping manufacturers meet tightening global regulations and safeguard device and patient safety
Subscribe now